Abstract #1199

The multi-centre iBEAt study: A comprehensive multi-parametric MR imaging biomarker panel for Diabetic Kidney Disease

Kanishka Sharma¹, Fotios Tagkalakis¹, Irvin Teh², Christopher Kelly², David Shelley³, Virva Saunavaara⁴, Dmitry Kuznetsov⁵, Anil Karihaloo⁶, Michael Mansfield³, Mark Gilchrist⁷, Roberto De Blasi⁸, Mark Ibberson⁵, Maria-Alexandra Olaru⁹, Bernd Kühn⁹, Nicolas Grenier¹⁰, and Steven Sourbron¹

¹Leeds Imaging Biomarkers Group, Biomedical Imaging Science Department, LICAMM, University of Leeds, Leeds, United Kingdom, ²Biomedical Imaging Science Department, LICAMM, University of Leeds, Leeds, United Kingdom, ³University of Leeds, Leeds, United Kingdom, ⁴University of Turku, Turku, Finland, ⁵Swiss Institute of Bioinformatics, Lausanne, Switzerland, ⁶Novo Nordisk, Bagsværd, Denmark, ⁷University of Exeter, Exeter, United Kingdom, ⁸University of Bari, Bari, Italy, ⁹Siemens Healthcare GmbH, Erlangen, Germany, ¹⁰University of Bordeaux, Bordeaux, France

There is a major clinical need for better biomarkers to identify Diabetic Kidney Disease (DKD) patients at risk of progression. iBEAt is a prospective multi-centre cohort study in 500 patients aiming to determine if MRI biomarkers can provide prediction of progression. We have developed a dedicated MRI biomarker panel for iBEAt interrogating body composition, renal morphology and tissue structure, hemodynamics and filtration. Here we present the details as well as example data and preliminary results on the ISMRM/NIST phantom, and on healthy volunteers.

This abstract and the presentation materials are available to members only; a login is required.

Join Here